Verastem Inc (VSTM) Actualités

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that...

Verastem Oncology to Present Mature RAMP 201 Data in Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society 2024 Annual Meeting

Late-breaking abstract of the mature RAMP 201 data evaluating avutometinib plus defactinib in low-grade serous ovarian cancer to be featured as...

Verastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024

LGSOC is a rare ovarian cancer often affecting younger women, with no FDA-approved treatments Approximately 80% of people treated for LGSOC will...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Verastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Updates

Initiated rolling NDA submission for avutometinib and defactinib combination in recurrent low-grade serous ovarian cancer in Q2 2024 with plans...

Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer

Expect to report updated data from the ongoing RAMP 205 trial in first-line metastatic pancreatic cancer in Q1 2025 Verastem Oncology (Nasdaq:...

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Verastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded Warrants

Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the...

Form 424B5 - Prospectus [Rule 424(b)(5)]